PR Newswire07.28.21
Medtronic plc gained U.S. Food and Drug Administration (FDA) clearance for two AccuRhythm AI algorithms for use with the LINQ II insertable cardiac monitor (ICM). AccuRhythm AI applies artificial intelligence (AI) to heart rhythm event data collected by LINQ II, improving the accuracy of information physicians receive so they can better diagnose and treat abnormal heart rhythms. AccuRhythm AI validation data will be presented this week at Heart Rhythm 2021, the Heart Rhythm Society's annual Heart Rhythm meeting.
The small, wireless LINQ II ICM is the world's most accurate ICM,1-4 and the new cloud-based AccuRhythm AI algorithms further enhance LINQ II ICM's delivery of accurate heart rhythm alerts. The algorithms address the two most common ICM false alerts—atrial fibrillation (AF), an irregular or rapid rhythm in the upper chambers of the heart; and asystole, a long pause between heartbeats.5-6 Medtronic developed the AccuRhythm AI platform and initial algorithms using its proprietary, diverse and debiased database of more than 1 million electrocardiogram heart rhythm episodes.
AccuRhythm AI validation results to be presented at Heart Rhythm 2021 include:
"Applying AccuRhythm AI to LINQ II data is a significant ICM innovation, enabling us to reduce clinical inefficiencies resulting from false alerts, and help physicians better identify and focus on the actionable data they need to treat their patients," said Rob Kowal, M.D., Ph.D., chief medical officer of Medtronic’s Cardiovascular Diagnostics and Services business.
The AccuRhythm AI algorithms will be released on the CareLink Network later this year for use by all implanted LINQ II devices in the United States.
"We are excited to integrate AI capabilities to further elevate the accuracy of LINQ II ICM—and provide clinicians with greater confidence in patient care decisions," said Julie Brewer, president of Medtronic’s Cardiovascular Diagnostics and Services business. "We look forward to introducing additional diagnostic innovations to advance patient management in the future."
References
1 BiotronikBioMonitor 2 Technical Manual. 2017.
2 NölkerG, et al. J Cardiovasc Electrophysiol. 2016;27:1403-1410.
3 Confirm Rx ICM DM3500 FDA Clearance Letter. 2017.
4 PürerfellnerH, et al. Europace. 2018;20:f321-f328.
5 Catherine O`Shea, Melissa E. Middeldorp, Anthony G. Brooks, Jeroen M. Hendriks, Celine Gallagher, Niraj Varma, Rakesh Gopinathannair, Suzanne A. Feigofsky, Dennis H. Lau, Kevin R. Campbell, Prashanthan Sanders. Remote Monitoring Of Implantable Loop Recorders: False-positive Alert Episodes. Poster presented at: HRS 2020 Science Online. May 2020. https://cslide-us.ctimeetingtech.com/hrs20/attendee/eposter/poster/71.
6 AccuRhythm Clinician Manual Supplements M015316C001 and M015314C001.
The small, wireless LINQ II ICM is the world's most accurate ICM,1-4 and the new cloud-based AccuRhythm AI algorithms further enhance LINQ II ICM's delivery of accurate heart rhythm alerts. The algorithms address the two most common ICM false alerts—atrial fibrillation (AF), an irregular or rapid rhythm in the upper chambers of the heart; and asystole, a long pause between heartbeats.5-6 Medtronic developed the AccuRhythm AI platform and initial algorithms using its proprietary, diverse and debiased database of more than 1 million electrocardiogram heart rhythm episodes.
AccuRhythm AI validation results to be presented at Heart Rhythm 2021 include:
- The AF algorithm reduced LINQ II ICM false AF alerts by 74.1 percent and preserved 99.3 percent of true AF alerts.
- The Pause algorithm reduced LINQ II false pause alerts by 97.4 percent and preserved 100 percent of true pause alerts.
"Applying AccuRhythm AI to LINQ II data is a significant ICM innovation, enabling us to reduce clinical inefficiencies resulting from false alerts, and help physicians better identify and focus on the actionable data they need to treat their patients," said Rob Kowal, M.D., Ph.D., chief medical officer of Medtronic’s Cardiovascular Diagnostics and Services business.
The AccuRhythm AI algorithms will be released on the CareLink Network later this year for use by all implanted LINQ II devices in the United States.
"We are excited to integrate AI capabilities to further elevate the accuracy of LINQ II ICM—and provide clinicians with greater confidence in patient care decisions," said Julie Brewer, president of Medtronic’s Cardiovascular Diagnostics and Services business. "We look forward to introducing additional diagnostic innovations to advance patient management in the future."
References
1 BiotronikBioMonitor 2 Technical Manual. 2017.
2 NölkerG, et al. J Cardiovasc Electrophysiol. 2016;27:1403-1410.
3 Confirm Rx ICM DM3500 FDA Clearance Letter. 2017.
4 PürerfellnerH, et al. Europace. 2018;20:f321-f328.
5 Catherine O`Shea, Melissa E. Middeldorp, Anthony G. Brooks, Jeroen M. Hendriks, Celine Gallagher, Niraj Varma, Rakesh Gopinathannair, Suzanne A. Feigofsky, Dennis H. Lau, Kevin R. Campbell, Prashanthan Sanders. Remote Monitoring Of Implantable Loop Recorders: False-positive Alert Episodes. Poster presented at: HRS 2020 Science Online. May 2020. https://cslide-us.ctimeetingtech.com/hrs20/attendee/eposter/poster/71.
6 AccuRhythm Clinician Manual Supplements M015316C001 and M015314C001.
